Dewhurst Martin William 4

What Happened
Martin W. Dewhurst, a director of Turn Therapeutics (TTRX), received a grant of 21,882 restricted stock units (RSUs) on January 7, 2026. The Form 4 reports an acquisition price of $0.00 for these RSUs (typical for award grants); they represent a contingent right to receive one share per RSU upon vesting.

Key Details

• Transaction date: 2026-01-07; filing date: 2026-02-04 (filed ~28 days after the grant; outside the typical 2-business-day Form 4 window).
• Reported transaction: Award/Grant (A) — 21,882 RSUs @ $0.00.
• Vesting: The 21,882 RSUs vest in full on January 7, 2027, subject to Dewhurst’s continuous service and the Issuer’s 2025 Omnibus Incentive Plan (per the filing footnote).
• Shares owned after transaction: Not specified in the provided filing data.
• Footnote: RSUs are a contingent right to receive common stock at vesting; no immediate transfer of shares occurred.

Context
RSU grants to directors are commonly used as compensation and do not represent an immediate purchase or sale of stock. These RSUs only convert into actual shares if vesting conditions (here, continuous service through Jan 7, 2027) are met. The delayed filing means the record of the grant appeared on the Form 4 several weeks after the grant date; investors should note timeliness but not assume intent from a compensation award alone.